Testosterone gel

Testosterone gel is a clear, colorless hydroalcoholic gel containing 1% testosterone. It provides continuous trans-dermal delivery of testosterone, the primary circulating endogenous androgen, for 24 hours following a single application to intact, clean, dry skin of the shoulders, upper arms, or abdomen. A daily application of 5, 7.5, or 10 g contains 50, 75, or 100 mg of testosterone, respectively, to be applied daily to the skin surface. Approximately 10% of the applied testosterone dose is absorbed 

---

Testosterone gel (Androgel) is applied once daily (preferably in the morning) to clean, dry, intact skin of die shoulders and upper arms or abdomen. After die packet is opened, die contents are squeezed into die palm of die hand and immediately applied to the application sites. The application sites are allowed to dry before die patient gets dressed. The gel is not applied to die genitals. 

Testosterone gel AndroGel 1%, Testim 5-10 g daily to shoulders, upper arms, or abdomen (AndroGel only) Once daily... 

Testosterone gel (AndroGel 1 °/o) 5 g2pkt, lOg/pkt 5-10 g/day apply to shoul ders, upper arms, abdomen... 

Testosterone Gel For replacement therapy in male with testosterone deficiencies and hypogonadotropic hypoganadism... 

Testosterone gel is effective transdermally, although a report on its use in the form of AA2500 (brand name), which releases 50 or 100 mg/day, points to an unusually high incidence of local sensitivity reactions it is not clear whether this is due to testosterone itself or to excipients absent from the placebo comparator (61). 

Orengo CA, Fullerton L, Kunik ME. Safety and efficacy of testosterone gel 1% augmentation in depressed men with partial response to antidepressant therapy. J Geriat Psychiatry Neurol 2005 18 20-4. 

Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003 88 2673-8. 

Ebert T, Jockenhovel F, Morales A, Shabsigh R. The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel. Eur Urol 2005 47 137-46. 

Dobs AS, Matsumoto AM, Wang C, Kipnes MS. Shortterm pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. Curr Med Res Opin 2004 20 729-38. 

Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, Swerdloff RS. Long-term testosterone gel (Androgel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004 89 2085-98. 

Testosterone gel Testoderm, Andro-derm Androgen deficiency Transdermal... 

Shabsigh R, Kaufman JM, Steidle C, et al. Randomised study of testosterone gel as adjunctive therapy to sildenafil in hypogo-nadal men with erectile dysfunction who do not response to sildenafil alone. J Urol 2004 172 658-663. 

R. S. Pharmacokinetics of transdermal testosterone gel in hypogonadal men apphcation of gel at one site versus four sites a general chnical research center study. J. Clin. Endocrinol. Metab. 2000, 85, 964—969. 

Mazer N, Fisher D, Fischer J, et al. Transfer of transdermal apphed testosterone to clothing a comparison of a testosterone patch versus a testosterone gel. J Sex Med 2005 2(2) 227-234. 

Testosterone gel 1% formulation (Androgel) is applied in much larger doses—5 or 10 g each day—to the skin of the shoulders, upper arms, or abdomen. The hormone is absorbed quickly, within 30 minutes, but it may take several hours for complete absorption of the dose. For this reason, the patient should be reminded to wait at least 5 to 6 hours after application before showering. To prevent inadvertent transfer of testosterone gel to others, the patient should thoroughly wash his hands with soap and water after administration of a dose. 

Mazer, N Bell, D., Wu, J., Fischer, J., Cosgrove, M. and Eilers, B. (2005) Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men. Journal of Sexual Medicine, 2, 213-226. 

The goal of testosterone therapy in hypogonadal men is to mimic as closely as possible the normal serum concentration therefore, serum testosterone concentration must be monitored. With transdermal patches, the serum testosterone concentration fluctuates during the 24-hour period, with a peak value 6—9 hours after application and a nadir (about 50% of the peak) just before the next patch is applied (Figure 58-6). With testosterone gels, the mean serum testosterone concentration is relatively constant from one application to the next. Occasional random fluctuations can occur, so measurements should be repeated for any dose. When the enanthate or cypionate esters of testosterone are administered once every 2 weeks (typically in a dose of200 mg), the serum testosterone concentration measured midway between doses should be normal if not, the dose should be adjusted accordingly. 

Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogo-nadal men 1. The Journal of Clinical Endocrinology and Metabolism. 2000 85(8) 2839-2853. 

White WB, Grady D, Giudice LC, Berry SM, Zborowski J, and Snabes MC. A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder. American Heart Journal. 2012 163 27-32. doi 10.1016/j.ahj.2011.09.021. 

Cardiovascular In a study in older men with limited mobility and a high prevalence of chronic diseases, the use of testosterone gel was associated with an increased risk of cardiovascular adverse events [43 ]. However, the small size of the trial and the particular nature of the population studied prevented broader inferences from being made about the safety of testosterone therapy. 

In 122 men, mean age 70 years, who were randomized to testosterone gel 5 g/ day in =61) or 10 g/day with different doses of growth hormone (0, 3, or 5 micro-grams/kg/day) for 12 weeks, there was an increase in blood pressure, which persisted 4 weeks after the study ended [12 ]. The blood pressure at 16 weeks was 130/ 76 mmHg compared with 117/68 mmHg at baseline. 

Geyer, H., Flenker, U., Mareck, U., et al. (2007) The detection of the misuse of testosterone gel, in Recent Advances in Doping Analysis (eds W. Schanzer, H. Geyer, A. Gotzmann, and U. Mareck), Sport Buch Strauss, Cologne, pp. 133-142. 

---